Intelligence Feed event · Policy · 2026-09-26

    C4 Therapeutics Presents Cemsidomide Phase 1/1b Myeloma Biomarker Data

    Question

    C4 Therapeutics Presents Cemsidomide Phase 1/1b Myeloma Biomarker Data

    Direct answer

    C4 Therapeutics delivered Phase 1 and Phase 1b clinical biomarker findings evaluating cemsidomide across relapsed/refractory multiple myeloma cohorts at the International Myeloma Society congress. Data highlighted meaningful T-cell recruitment and immune cell modulation when paired with standard and novel therapeutic agents like elranatamab.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-26
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “C4 Therapeutics Presents Cemsidomide Phase 1/1b Myeloma Biomarker Data”, revision 1, evidence through 2026-09-26. https://marketontology.com/market-events/2026-09-26/c4-therapeutics-presents-cemsidomide-phase-1-1b-myeloma-biomarker-data-75ac53

    POLICY
    C4 Therapeutics Presents Cemsidomide Phase 1/1b Myeloma Biomarker Data
    C4 Therapeutics delivered Phase 1 and Phase 1b clinical biomarker findings evaluating cemsidomide across relapsed/refractory multiple myeloma cohorts at the International Myeloma Society congress. Data highlighted meaningful T-cell recruitment and immune cell modulation when paired with standard and novel therapeutic agents like elranatamab.
    CCCCPFE
    Impact
    61
    SEP 26
    SIG
    88%
    CCCCPFE
    C4 Therapeutics Presents Cemsidomide Phase 1/1b Myeloma Biomarker Data
    C4 Therapeutics delivered Phase 1 and Phase 1b clinical biomarker findings evaluating cemsidomide across relapsed/refractory multiple myeloma cohorts at the International Myeloma Society congress. Data highlighted meaningful T-cell recruitment and immune cell modulation when paired with standard and novel therapeutic agents like elranatamab.
    → Positive translational oncology data strengthens degrader platform validation, supporting commercial partnership valuation.
    Impact
    C4 Therapeutics delivered Phase 1 and Phase 1b clinical biomarker findings evaluating cemsidomide across relapsed/refractory multiple myeloma cohorts at the International Myeloma Society congress. Data highlighted meaningful T-cell recruitment and immune cell modulation when paired with standard and novel therapeutic agents like elranatamab.
    Affected
    CCCCPFE
    Transmission
    Positive translational oncology data strengthens degrader platform validation, supporting commercial partnership valuation.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CCCCbiotech pipeline derisking via validated Phase 1 biomarker mechanismsUp1-5dPresented positive biomarker and T-cell activation data at 23rd IMS Annual Meeting.
    PFEcombination therapy efficacy expansion for ELREXFIO franchiseUp1-4wC4 testing combination of cemsidomide with Pfizer's elranatamab.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    CCCCUpdisagreed2.98 2026-09-25+4.53%-1.01%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month